JCR Pharmaceuticals gets Japan orphan drug designation for givinostat

Japan's health ministry granted orphan drug designation to givinostat for Duchenne muscular dystrophy. JCR said it is advancing development in Japan and plans to submit a marketing authorization application by end-2026.